Stockpolly
Search
Delisting risk
ACXP · NASDAQ · Biotechnology

Acurx Pharmaceuticals (ACXP)

Developing selective-spectrum antibiotics for C. difficile and other Gram-positive infections.

$1.42
Pre-market−0.02 (−1.05%)
At close$1.44(+2.50%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
354433222222
Research & development1222111101,83301
2332222226,2531,3751
Selling & marketing000000000−200
General & administrative2332222226,2541,3751
Other expenses0—00———00−8,084−1,3730
Operating income−3−5−4−4−3−3−2−2−2−2−2−2
0—00—0—00000
Interest income000000000000
Other non-operating income0—00—0—00000
Income before tax−3−5−4−4−3−3−2−2−2−2−2−2
Net income from continuing operations−3−5−4−4−3−3−2−2−2−2−2−2
Net income−3−5−4−4−3−3−2−2−2−2−2−2
EPS, basic−$4.79−$7.60−$5.66−$5.21−$3.45−$3.27−$2.14−$1.89−$1.23−$0.67−$1.12−$0.53
EPS, diluted−$4.79−$7.60−$5.66−$5.21−$3.45−$3.27−$2.14−$1.89−$1.23−$0.67−$1.12−$0.53
Weighted average shares, basic111111112114
Weighted average shares, diluted111111112114
EBITDA00−4−4000−2−2−2−2−2
Depreciation & amortization350033200000
EBIT−3−5−4−4−3−3−2−2−2−2−2−2